دورية أكاديمية
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin:The Randomized, Controlled EMPA-VISION Trial
| العنوان: | Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin:The Randomized, Controlled EMPA-VISION Trial |
|---|---|
| المؤلفون: | Hundertmark, Moritz J., Adler, Amanda, Antoniades, Charalambos, Coleman, Ruth, Griffin, Julian L., Holman, Rury R., Lamlum, Hanan, Lee, Jisoo, Massey, Daniel, Miller, Jack J.J.J., Milton, Joanne E., Monga, Shveta, Mózes, Ferenc E., Nazeer, Areesha, Raman, Betty, Rider, Oliver, Rodgers, Christopher T., Valkovič, Ladislav, Wicks, Eleanor, Mahmod, Masliza, Neubauer, Stefan |
| المصدر: | Hundertmark , M J , Adler , A , Antoniades , C , Coleman , R , Griffin , J L , Holman , R R , Lamlum , H , Lee , J , Massey , D , Miller , J J J J , Milton , J E , Monga , S , Mózes , F E , Nazeer , A , Raman , B , Rider , O , Rodgers , C T , Valkovič , L , Wicks , E , Mahmod , M & Neubauer , S 2023 , ' Assessment of Cardiac Energy .... |
| سنة النشر: | 2023 |
| المجموعة: | Aarhus University: Research |
| مصطلحات موضوعية: | empagliflozin, heart failure, magnetic resonance spectroscopy, sodium-glucose transporter proteins |
| الوصف: | Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness. Methods: EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated. Results: Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin - placebo], -0.25 [95% CI, -0.58 to 0.09]; P=0.14) or HFpEF (adjusted mean treatment ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://pure.au.dk/portal/en/publications/06821eb7-dc78-4441-a6b4-a23ac2bcfaf6Test |
| DOI: | 10.1161/CIRCULATIONAHA.122.062021 |
| الإتاحة: | https://doi.org/10.1161/CIRCULATIONAHA.122.062021Test https://pure.au.dk/portal/en/publications/06821eb7-dc78-4441-a6b4-a23ac2bcfaf6Test http://www.scopus.com/inward/record.url?scp=85160841739&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.9A0C7B7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/CIRCULATIONAHA.122.062021 |
|---|